medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 6

<< Back Next >>

Ann Hepatol 2015; 14 (6)

Prevalence of hepatitis B and C markers in a population of an urban university in Rio de Janeiro, Brazil: a cross-sectional study

Pinto FPD, Ferreira JOC, Olmedo DB, Precioso PM, Barquette FRS, Castilho MC, Silva, SGC, Pôrto LC

Language: English
References: 31
Page: 815-825
PDF size: 123.12 Kb.


ABSTRACT

Background and rationale. Epidemics of hepatitis B and C are a public health burden, and their prevalence in Brazil varies among regions. We determined the prevalence of hepatitis markers in an urban university population in order to support the development of a comprehensive program for HBV immunization and HBV/HCV diagnosis. Students, employees, and visitors (n = 2,936, 31 years IQR 24.5-50, female = 69.0% and 81.1% with at least 12 years of education) were enrolled from May to November 2013. Antibodies against hepatitis B surface antigen (anti-HBs), against hepatitis B core antigen (anti-HBc), and hepatitis B surface antigen (HBsAg) were detected with enzyme immunoassays and anti-hepatitis C virus (anti-HCV) antibodies with a chemiluminescence immunoassay. The results were confirmed with polymerase chain reaction for HCV and nucleic acid amplification test for hepatitis B virus (HBV). Results. The overall prevalence of markers among the participants was 0.136% (95% confidence interval [CI]: 0.003-0.270) for HBsAg, 6.44% (95% CI: 5.55-7.33%) for anti-HBc, 50.8% (95% CI: 48.9-52.7%) for anti-HBs › 10 mIU/mL, and 0.44% (95% CI: 0.20-0.68) for anti-HCV. Almost 30.4% had anti-HBs titers › 100 mIU/mL. Participants with a detectable HCV viral load (n = 9) were infected with genotype 1a. Conclusions. In an urban university population, in which 80% of participants had › 11 years of education, prevalence increased with age, and self-declared ethnicity for anti-HBc and with age, marital status and professional activity for anti-HCV antibodies. A periodical offer of HCV rapid testing should be implemented, and HBsAg rapid testing should be offered to individuals above 20 years of age.


REFERENCES

  1. Lee MH, Yang HI, Yuan Y, L’Italien G, Chen CJ. Epidemiology and natural history of hepatitis C virus infection. World J Gastroenterol 2014; 20; 9270-80.

  2. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses; a global overview. Clin Liver Dis 2010; 14; 1-21.

  3. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection; new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57; 1333-42.

  4. Bruggmann P, Berg T, Ovrehus AL, Brandao Mello CE, Roudot- Thoraval F, Marinho RT, Sherman M, et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat 2014; 21(Suppl. 1); 5-33.

  5. WHO Fact sheet N°204. Available at: http:// www.who.int/mediacentre/factsheets/fs204/en/

  6. Gerlich WH. Medical virology of hepatitis B; how it began and where we are now. Virol J 2013; 10: 239.

  7. Lavanchy D. Viral hepatitis; global goals for vaccination. J Clin Virol 2012; 55: 296-302.

  8. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014.

  9. Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, Ormeci N, et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 2014; 21: 60-89.

  10. IBGE; Censo Demográfico 2010. Características da População e dos Domicílios. Resultados do Universo. In: Rio de Janeiro; IBGE, 2011.

  11. Ximenes RA, Pereira LM, Martelli CM, Merchan-Hamann E, Stein AT, Figueiredo GM, Braga MC, et al. Methodology of a nationwide cross-sectional survey of prevalence and epidemiological patterns of hepatitis A, B and C infection in Brazil. Cad Saude Publica 2010; 26; 1693-704.

  12. Domingues CMAS, Lins Neto AA, Verotti MP, Burgos Filho R. Ampliação da oferta da vacina de Hepatite B para a faixa etária de 30 a 49 anos em 2013. In: Vigilância das Doenças Transmissíveised. Brazil; Ministério da Saúde, 2013.

  13. Ribeiro JE, Oliveira RSM, Hallal RC. Protocolo clínico e diretrizes terapêuticas para hepatite viral C e coinfecções In; DST, Aids e Hepatites viraised. Brasilia; Minisério da Saúde, 2011.

  14. Carvalho P, Schinoni MI, Andrade J, Vasconcelos Rego MA, Marques P, Meyer R, Araujo A, et al. Hepatitis B virus prevalence and vaccination response in health care workers and students at the Federal University of Bahia, Brazil. Ann Hepatol 2012; 11: 330-7.

  15. de Almeida-Neto C, Sabino EC, Liu J, Blatyta PF, Mendrone- Junior A, Salles NA, Leao SC, et al. Prevalence of serologic markers for hepatitis B and C viruses in Brazilian blood donors and incidence and residual risk of transfusion transmission of hepatitis C virus. Transfusion 2013; 53: 827-34.

  16. Pereira LM, Martelli CM, Merchan-Hamann E, Montarroyos UR, Braga MC, de Lima ML, Cardoso MR, et al. Populationbased multicentric survey of hepatitis B infection and risk factor differences among three regions in Brazil. Am J Trop Med Hyg 2009; 81: 240-7.

  17. Tabor E, Gerety RJ, Smalwood LA, Barker LF. Coincident hepatitis B surface antigen and antibodies of different subtypes in human serum. J Immunol 1977; 118: 369-70.

  18. Gerlich WH.The enigma of concurrent hepatitis B surface antigen (HBsAg) and antibodies to HBsAg. Clin Infect Dis 2007; 44: 1170-2.

  19. Lada O, Benhamou Y, Poynard T, Thibault V. Coexistence of Hepatitis B surface antigen (HBsAg) and anti-HBs antibodies in chronic hepatitis B virus carrier: influence of “a” determinant variants. J Virol 2006; 80: 2968-75.

  20. Zhang J-M, Xu Y, Wang X-Y, Wu X-H, Weng X-H, Lu M. Coexistence of Hepatitis B surface antigen (HBsAg) and heterologous subtype-specific antibodies to HBsAg among patients with chronic hepatitis B virus infection. Clin Infect Dis 2007; 44: 1161-8.

  21. Minuk GY, Huynh C, Uhanova J, Osiowy C. Establishing diagnostic criteria for occult hepatitis B virus infections in community based populations. J Med Virol 2014; 86: 156-61.

  22. de la Fuente RA, Gutierrez ML, Garcia-Samaniego J, Fernandez- Rodriguez C, Lledo JL, Castellano G. Pathogenesis of occult chronic hepatitis B virus infection. World J Gastroenterol 2011; 17: 1543-8.

  23. Rosini N, Mousse D, Spada C, Treitinger A. Seroprevalence of HbsAg, Anti-HBc and anti-HCV in Southern Brazil, 1999- 2001. Braz J Infect Dis 2003; 7: 262-7.

  24. Lewis-Ximenez LL, do OK, Ginuino CF, Silva JC, Schatzmayr HG, Stuver S, Yoshida CF. Risk factors for hepatitis B virus infection in Rio de Janeiro, Brazil. BMC Public Health 2002; 2: 26.

  25. Pereira LM, Martelli CM, Moreira RC, Merchan-Hamman E, Stein AT, Cardoso MR, Figueiredo GM, et al. Prevalence and risk factors of Hepatitis C virus infection in Brazil, 2005 through 2009; a cross-sectional study. BMC Infect Dis 2013; 13: 60.

  26. Braga WS, Castilho MC, Borges FG, Martinho AC, Rodrigues IS, Azevedo EP, Scazufca M, et al. Prevalence of hepatitis B virus infection and carriage after nineteen years of vaccination program in the Western Brazilian Amazon. Rev Soc Bras Med Trop 2012; 45: 13-7.

  27. Fernandes L, Burnett RJ, Francois G, Mphahlele MJ, Van Sprundel M, De Schryver A. Need for a comprehensive, consistently applied national hepatitis B vaccination policy for healthcare workers in higher educational institutions; a case study from South Africa. J Hosp Infect 2013; 83: 226-31.

  28. Saffar H, Ajami A, Saffar MJ, Shojaei J, Sotudeh-Anvari M, Shams-Esfandabad K, Khalilian AR. Prevalence of hepatitis B virus seromarkers in young adults vaccinated at birth; impact on the epidemiology of hepatitis B infection in Iran. Hepat Mon 2014; 14; e17263.

  29. Amponsah-Dacosta E, Lebelo RL, Rakgole JN, Burnett RJ, Selabe SG, Mphahlele MJ. Evidence for a change in the epidemiology of hepatitis B virus infection after nearly two decades of universal hepatitis B vaccination in South Africa. J Med Virol 2014; 86: 918-24.

  30. Oliveira SAN, Hacker MA, Oliveira MLA, Yoshida CFT, Telles PR, Bastos FI. A window of opportunity; declining rates of hepatitis B virus infection among injection drug users in Rio de Janeiro, and prospects for targeted hepatitis B vaccination. Rev Panam Salud Publica 2005; 18: 271-7.

  31. Ribeiro JE, Hallal RC. Protocolo Clínico e Diretrizes Terapêuticas para Hepatite Viral C e Coinfecções. Manejo do paciente infectado cronicamente pelo genótipo 1 do HCV e fibrose avançada. In: DST, Aids e Hepatites viraised. Brasília; Ministério da Saúde, 2013.




2020     |     www.medigraphic.com